The prominence of photodynamic therapy (PDT) in treating superficial skin cancer inspires
innovative solutions for its congenitally deficient shadow penetration of the visible-light …

Oncology research in humans is limited to analytical and observational studies for obvious
ethical reasons, with therapy-focused clinical trials being the one exception to this rule …

Lysine-specific demethylase 6A (KDM6A), also named UTX, is frequently mutated in bladder
cancer (BCa). Although known as a tumor suppressor, KDM6A's therapeutic potential in the …

Bladder cancer is a common malignancy that has a relatively poor outcome. Lack of culture
models for the bladder epithelium (urothelium) hampers the development of new …

Cisplatin-based chemotherapy remains the primary treatment for unresectable and
metastatic muscle-invasive bladder cancers (MIBCs). However, tumors frequently develop …

Intratumoral heterogeneity is a critical factor when diagnosing and treating patients with
cancer. Marked differences in the genetic and epigenetic backgrounds of cancer cells have …

Purpose: Epigenetic deregulation is deeply implicated in the pathogenesis of bladder
cancer. KDM6A (Lysine (K)-specific demethylase 6A) is a histone modifier frequently …

Abstract The N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) mouse model is an attractive
model system of muscle-invasive bladder cancer (MIBC) as it recapitulates the histology of …

In human and dogs, bladder cancer (BC) is the most common neoplasm affecting the urinary
tract. Dog BC resembles human muscle‐invasive BC in histopathological characteristics and …

Intravesical chemotherapy is generally used in the clinic for treating bladder cancer (BCa),
but its efficacy is limited due to the permeation barrier and side effects caused by the off …